Sign in
4

Changes in Ownership

Viking Therapeutics, Inc. Filed Acc 0001209191-24-003010

President & CEO sold 269,079 shares at an average $26.87 ($7,230,784)

  • President & CEO acquired 189,079 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Lian Brian · President & CEO

Table I: Non-derivative

7 lines
Date Transaction Shares Price Value Owned after D/I
2024-02-08 Exercise or conversion : show line 1 in the form 10b5-1 +49,079 $1.23 $60,367 2,313,961 D
2024-02-08 Sale : show line 2 in the form 10b5-1 −49,079 $25.75 $1,263,784 2,264,882 D
2024-02-08 Exercise or conversion : show line 3 in the form 10b5-1 +140,000 $4.65 $651,000 2,404,882 D
2024-02-08 Sale : show line 4 in the form 10b5-1 −60,000 $25.95 $1,557,000 2,344,882 D
2024-02-08 Sale : show line 5 in the form 10b5-1 −80,000 $26.95 $2,156,000 2,264,882 D
2024-02-08 Sale : show line 6 in the form 10b5-1 −40,000 $27.45 $1,098,000 2,224,882 D
2024-02-08 Sale : show line 7 in the form 10b5-1 −40,000 $28.90 $1,156,000 2,184,882 D
Open-market sales · 269,079 sh · avg $26.87 · $7,230,784

Table II: Derivative

3 lines
Date Transaction Shares Owned after D/I
2024-02-08 Exercise or conversion : show line 8 in the form 10b5-1 Stock Option (right to buy) −14,148 0 D
2024-02-08 Exercise or conversion : show line 9 in the form 10b5-1 Stock Option (right to buy) −34,931 0 D
2024-02-08 Exercise or conversion : show line 10 in the form 10b5-1 Stock Option (right to buy) −140,000 0 D
Loading xslF345X05/doc4.xml…